Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
The Summermatter cycle is a physiological concept describing the complex relationship between physical activity/inactivity and energy expenditure/conservation. The concept provides an evidence-based explanation why dieting fails in most cases and results in a Yo-yo effect. A central element of the Summermatter cycle is that reductions in energy intake, occurring with dieting or starvation, initially successfully induce weight and adipose tissue loss. At the same time, the reduced food availability prompts ambulatory activity, which further accelerates body and fat mass loss and depletes ATP, glycogen and intramyocellular lipids (IMCL) in skeletal muscle. The scarcity of energy ultimately suppresses thermogenesis in skeletal muscle to conserve energy. As soon as energy becomes available again, this originally adaptive, thrifty program supports the replenishment of energy stores and weight regain. Fat deposition is the most efficient way for the body to store energy. This phenomenon of energy store replenishment is driven by a hyperinsulinemic state and is referred to as preferential catch-up fat. Satiety signals during the period of food availability automatically lead to rest, which further supports adipose tissue regain and the restoration of glycogen and IMCL pools in muscle. As a result, the majority of people rapidly regain body weight. Exercise increases energy expenditure and can counteract the suppression of thermogenesis in skeletal muscle thereby preventing weight regain. In addition, regular exercise promotes the turnover of ATP, glycogen and IMCLs.
In addition, seed collection is hampered by issues with the Convention on Biological Diversity, which regulates the ownership and international movement of genetic resources, but has been stuck in multilateral negotiations.
== External links == Amino acid metabolism Chapter on Amino acid catabolism in Biochemistry by Jeremy Berg, John Tymoczko, Lubert Stryer. Fourth ed. by Lubert Stryer. ISBN 0-7167-4955-6 Accessed 2007-03-17 Amino acid metabolism
Sources: en.wikipedia.org
Homotropic allosteric enzymes: substrate and effector play a part in the modulation of the enzyme, which affects the enzyme catalytic activity. Heterotropic allosteric enzymes: only the effector performs the role of modulation.
By September 1900, the British were nominally in control of both Republics, with the exception of north Transvaal. However, they discovered they only controlled the territory their columns physically occupied. Despite the loss of their capitals and half their army, the Boer commanders adopted guerrilla warfare, conducting raids against railways, resource and supply targets, aimed at disrupting the operational capacity of the British Army. They avoided pitched battles and casualties were light. Boer commando units were sent to the district from which its members were recruited, which meant they could rely on local support and knowledge of the terrain and towns, enabling them to live off the land. Their orders were simply to act against the British whenever possible. Their tactics were to strike fast causing as much damage as possible, then withdraw before enemy reinforcements could arrive. The vast distances of the republics allowed Boer commandos freedom to move about and made it nearly impossible for the 250,000 British troops to control the territory effectively using columns alone. As soon as a British column left a town or district, British control of that area faded away. Boer commandos were especially effective during the initial guerrilla phase because Roberts had assumed the war would end with the capture of the capitals and dispersal of the Boer armies. British troops were therefore redeployed out of the area, and had been replaced by lower-quality Imperial Yeomanry and locally-raised irregular corps.
== Optical properties == The organic ligands of the interfacial layer can influence the photoluminescence (PL) of a nanoparticle via various mechanisms, two of which are surface passivation and carrier trapping. Surface passivation: At the surface of an uncovered nanoparticle (without an interfacial layer) dangling atoms are found. These bonds form energy levels between the HOMO–LUMO gap, thereby leading to non-radiative relaxation. Due to the binding of ligand molecules with the dangling orbitals, the energy of these states is shifted away from the HOMO-LUMO gap. This prevents nonradiative relaxation, and thus results in more PL. The strength of this effect strongly depends on the type of ligands. In general, small, linear ligands, do better than bulky ligands, because they lead to a higher surface coverage density, therefore allowing more dangling orbitals to be passivated. Another surface effect is carrier trapping. Here the ligands can scavenge the electron(holes) in the nanoparticle, thereby precluding radiative recombination and thus leading towards a reduction in PL. A well-known example of such ligands are thiols. The light conversion efficiency can also be improved using an interfacial layer that exists of compounds that absorb in a wider energy range and emit at the absorption energy of the nanoparticle. According to C. S. Inagaki et al the absorption band of a metallic nanoparticle was shown to drastically increase in width, caused by the overlap of transitions in the interfacial layer and the plasmon resonance band of the nanoparticle.
Sources: en.wikipedia.org
Glycolysis is the metabolic pathway that converts glucose (C6H12O6) into pyruvate and, in most organisms, occurs in the liquid part of cells (the cytosol). The free energy released in this process is used to form the high-energy molecules adenosine triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH). Glycolysis is a sequence of ten reactions catalyzed by enzymes.
==== Chromatographic methods ==== A variety of chromatographic methods can be used to analyse YTXs. This includes chromatographic techniques coupled to mass spectrometry and fluorescence detectors. All of the chromatographic techniques require a calibration step prior to sample analysis.
=== Palmar and plantar aponeuroses and extensor hood === The palmar aponeuroses occur on the palms of the hands. The extensor hoods are aponeuroses at the back of the fingers. The plantar aponeuroses occur on the plantar aspect of the foot. They extend from the calcaneal tuberosity then diverge to connect to the bones, ligaments and the dermis of the skin around the distal part of the metatarsal bones.
== Mechanism of action == Icotrokinra is a targeted oral peptide that selectively binds to and blocks the interleukin 23 receptor (IL-23R), thereby inhibiting IL-23-mediated signaling. The drug demonstrates high affinity for the human IL-23 receptor with a dissociation constant (KD) of 7.1 pM and inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM. The IL-23 pathway plays a central role in the inflammatory cascade underlying various autoimmune conditions, particularly those involving Th17 cells. Unlike injectable biologics that target IL-23 or its receptor, icotrokinra offers the convenience of oral administration while maintaining selective receptor binding.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.